A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Clinical Trial ID NCT00875979

PubWeight™ 4.06‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00875979

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol 2014 0.91
2 Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. Breast Cancer (Auckl) 2014 0.87
3 Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer. Breast Cancer (Auckl) 2016 0.82
4 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
5 Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer. Onco Targets Ther 2016 0.75
Next 100